Avacta Group (AVCT) Competitors GBX 31.50 +0.50 (+1.61%) As of 04/25/2025 12:20 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock AVCT vs. SLN, PRTC, OXB, HZD, FARN, VRP, ARIX, CIR, 4BB, and BVXPShould you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Silence Therapeutics (SLN), PureTech Health (PRTC), Oxford Biomedica (OXB), Horizon Discovery Group plc (HZD.L) (HZD), Faron Pharmaceuticals Oy (FARN), Verona Pharma plc (VRP.L) (VRP), Arix Bioscience (ARIX), Circassia Group (CIR), 4basebio (4BB), and Bioventix (BVXP). These companies are all part of the "biotechnology" industry. Avacta Group vs. Silence Therapeutics PureTech Health Oxford Biomedica Horizon Discovery Group plc (HZD.L) Faron Pharmaceuticals Oy Verona Pharma plc (VRP.L) Arix Bioscience Circassia Group 4basebio Bioventix Silence Therapeutics (LON:SLN) and Avacta Group (LON:AVCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is SLN or AVCT more profitable? Silence Therapeutics has a net margin of 0.00% compared to Avacta Group's net margin of -114.45%. Silence Therapeutics' return on equity of 0.00% beat Avacta Group's return on equity.Company Net Margins Return on Equity Return on Assets Silence TherapeuticsN/A N/A N/A Avacta Group -114.45%-74.00%-21.80% Do institutionals and insiders believe in SLN or AVCT? 10.2% of Avacta Group shares are owned by institutional investors. 32.9% of Avacta Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the MarketBeat Community favor SLN or AVCT? Avacta Group received 9 more outperform votes than Silence Therapeutics when rated by MarketBeat users. However, 68.81% of users gave Silence Therapeutics an outperform vote while only 67.30% of users gave Avacta Group an outperform vote. CompanyUnderperformOutperformSilence TherapeuticsOutperform Votes20368.81% Underperform Votes9231.19% Avacta GroupOutperform Votes21267.30% Underperform Votes10332.70% Which has preferable valuation and earnings, SLN or AVCT? Silence Therapeutics has higher earnings, but lower revenue than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Silence Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilence Therapeutics£11.35M0.00N/A-£48.60N/AAvacta Group£26.29M4.55-£30.08M-£7.77-4.05 Does the media prefer SLN or AVCT? In the previous week, Silence Therapeutics had 2 more articles in the media than Avacta Group. MarketBeat recorded 2 mentions for Silence Therapeutics and 0 mentions for Avacta Group. Silence Therapeutics' average media sentiment score of 0.00 equaled Avacta Group'saverage media sentiment score. Company Overall Sentiment Silence Therapeutics Neutral Avacta Group Neutral SummaryAvacta Group beats Silence Therapeutics on 6 of the 11 factors compared between the two stocks. Get Avacta Group News Delivered to You Automatically Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVCT vs. The Competition Export to ExcelMetricAvacta GroupBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£119.67M£120.43M£5.47B£2.56BDividend Yield3.97%3.69%5.43%4.84%P/E Ratio-4.053.0022.39132.22Price / Sales4.554,221.42391.41241,113.66Price / Cash15.0013.0238.1828.31Price / Book2.1434.746.684.53Net Income-£30.08M-£90.45M£3.22B£5.86B7 Day Performance-11.96%4.30%6.25%8.61%1 Month Performance-17.04%-0.28%-2.81%6.37%1 Year Performance-33.22%88.94%16.47%103.30% Avacta Group Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVCTAvacta GroupN/AGBX 31.50+1.6%N/A-30.0%£119.67M£26.29M-4.05120SLNSilence TherapeuticsN/AN/AN/AN/A£480.35M£11.35M-11.01100High Trading VolumePRTCPureTech Health1.7778 of 5 starsGBX 125.40-5.4%GBX 455+262.8%-42.2%£376.68M£521,320.79-5.14300High Trading VolumeOXBOxford BiomedicaN/AGBX 305+0.5%GBX 560+83.6%+36.1%£324.22M£98.31M-2.27891HZDHorizon Discovery Group plc (HZD.L)N/AN/AN/AN/A£302.98M£54.63M-33.55416FARNFaron Pharmaceuticals OyN/AGBX 205.20-2.3%N/A+55.3%£275.49MN/A-5.4934News CoverageGap DownVRPVerona Pharma plc (VRP.L)N/AN/AN/AN/A£228MN/A-1.6822Gap UpARIXArix BioscienceN/AN/AN/AN/A£183.73M£14.16M1,290.919CIRCircassia GroupN/AN/AN/AN/A£142.66M£27.90M3,400.00111Gap Down4BB4basebioN/AGBX 1,100.50-2.2%GBX 1,600+45.4%-1.8%£140.97M£311,000.00-1,410.90101Gap DownBVXPBioventixN/AGBX 2,538+1.5%N/A-41.5%£132.90M£13.65M16.4112News CoverageGap Up Related Companies and Tools Related Companies Silence Therapeutics Alternatives PureTech Health Alternatives Oxford Biomedica Alternatives Horizon Discovery Group plc (HZD.L) Alternatives Faron Pharmaceuticals Oy Alternatives Verona Pharma plc (VRP.L) Alternatives Arix Bioscience Alternatives Circassia Group Alternatives 4basebio Alternatives Bioventix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AVCT) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAII predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avacta Group Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Avacta Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AVCT Stock Free AVCT Stock Alerts